

An abstract graphic featuring a hand pointing at a bar chart and a line graph. The background is a dark blue gradient with a white line graph and a dashed line graph. The hand is pointing at a bar chart with four bars of increasing height. A white line graph with a solid line and a dashed line is overlaid on the chart. The solid line starts at the bottom left and trends upwards to the top right, ending in an arrowhead. The dashed line starts at the bottom left and trends upwards to the top right, ending in an arrowhead. The bars are blue and of increasing height from left to right. The background is a dark blue gradient with a white line graph and a dashed line graph. The hand is pointing at a bar chart with four bars of increasing height. A white line graph with a solid line and a dashed line is overlaid on the chart. The solid line starts at the bottom left and trends upwards to the top right, ending in an arrowhead. The dashed line starts at the bottom left and trends upwards to the top right, ending in an arrowhead. The bars are blue and of increasing height from left to right.

# CLINICAL RESEARCH PRIMER


# Table of contents

Introduction .....	1	Statistical concepts.....	16
Clinical trial design terms .....	2	Anatomy of a clinical publication .....	26
Types of clinical studies .....	11	Evaluate like a competitor .....	36
Hierarchy of clinical evidence .....	14	No-panic checklist.....	43
Clinical study types in device approval of device by FDA .....	15	Bibliography .....	44

# Clinical trial design terms *(continued)*

## Stratification/stratified randomization

In some trials, patients may have important differences that researchers know will affect the outcome, such as different stages of disease. In these cases, patients may first be divided (stratified) into two or more groups according to key common characteristics, followed by randomizing those groups into sub-groups. Sometimes you will find that authors stratify in the analysis of data stage (i.e., it is a statistical stratification rather than a patient grouping stratification). An example of this is to stratify by age group: 20-29, 30-39, 40-49, etc.



## Bias

Bias can be introduced into a trial in a number of ways and can impact the results of a study.

Type of bias	Definition	Example
<b>Confounding bias</b>	When one or more variables is not taken into consideration.	Age, gender, co-existing medical conditions and/or prior use of healthcare facilities are a few of the variables which, if not explicitly accounted for, can alter the results of a study.
<b>Detection bias</b>	A biased assessment of outcome, possibly caused using a particular diagnostic technique or type of equipment.	Rates of breast cancer, for example, may vary in different geographic regions, not because of an actual difference in the incidence of the disease but because of the differences in access to diagnostics.
<b>Investigator bias</b>	The impact an investigator can have on the results.	An investigator who is convinced in a particular treatment might influence positive outcomes from the treatment (either intentional or unintentional).
<b>Patient bias</b>	<b>The impact patients themselves can have on the results.</b>	If study patients know they are in the control group, they may use other forms of care.
<b>Selection bias</b>	When patients are non-randomly allocated to comparison groups.	When individuals from the study group are drawn from one population (e.g., patients seen at the emergency room/department), and the control patients are drawn from another (e.g., clinic patients).

# Clinical trial design terms *(continued)*

## Minimizing bias

One way researchers can avoid bias is through “blinding.”

### Blinding

Similar to randomization, blinding helps limit or eliminate factors that could unconsciously influence results. As illustrated in the image below, there are several approaches to minimizing bias through blinding.

**Single blind** – Trial patients have no knowledge of which treatment they are receiving – Either interventional treatment or standard of care treatment.

*Example:* A study patient does not know if they are getting the study drug or placebo, but the investigator does.



**Double blind** – Trial patients and investigators have no knowledge of the trial group assignment.

*Example:* Neither the study patient nor investigator know if the patient is receiving the study drug or the placebo.



**Triple blind** – Trial patients, investigators and anyone else involved in evaluation of trial outcomes have no knowledge of the trial group assignment.

*Example:* Patients, investigators and sponsor are unaware if study patients are receiving the study drug or placebo. A third party randomizes this activity. This is made known only upon analysis of the results.



Rezaei is Director of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, and the Pittsburgh Vascular Surgery, Department, University College of Medicine, the Catholic University of Ireland, Ireland. He is also an adjunct faculty at the University of Pittsburgh Medical Center, Pittsburgh, PA.

Published online 11 November 2012 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1111/j.1365-3113.2012.04861.x

© 2012 Blackwell Publishing Ltd *Journal of Internal Medicine* 272: 105–110